Health: lung cancer, a plural tumor

In 2018, 46,363 new cases of lung cancer were identified in France. In men it is the second most common tumor among solid tumors and the third in women. In the same year, this tumor caused 33,117 deaths. Beyond these figures, the therapeutic progress of recent years offers a lot of hope.

Cancer of smokers but …

In 2018, 46,363 new cases of lung cancer were identified in France. In men it is the second most common tumor among solid tumors and the third in women. In the same year, this tumor caused 33,117 deaths. Beyond these figures, the therapeutic progress of recent years offers a lot of hope.

Cancer of smokers but also… of non-smokers

“The vast majority of lung cancers are caused by tobacco, particularly people who have been smoking for more than 20 years in general. But non-smokers can also be affected. In fact, we have identified other causes such as aging, pollution emitted by motor vehicles. In general, the main risk factors such as tobacco are cited by the French (85%). On the other hand, only 13% mention cannabis. “This is another risk factor to talk about, because it is often used on a regular basis. Just like the electronic cigarette. Finally, let’s not forget that lung cancer can be linked to genetic mutations. As Laure Guéroult-Accolas, president of the Patient Network Association, points out, “we all have lungs, we can all be affected”.

A multiform tumor

According to the Ipsos survey, among the most common cancers, lung cancer seems to be the most feared by the French (61% among men and 59% among women). But a third of the respondents are unaware that there are different forms of lung cancer. ‘There are two main types of lung cancer,’ says Professor Christos Chouaïd. “We are talking about non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLCs are the most common and account for approximately 80% of bronchial cancers. “

Personalized support

It’s not all. Among the NSCLCs, “some are associated with molecular anomalies which are very interesting as they open up the possibility of personalized treatment”, continues Professor Christos Chouaïd. “So, depending on the stage at diagnosis, the characteristics of the disease and the patient, different therapeutic options are available: surgery, chemotherapy, radiotherapy, immunotherapy and the emergence of targeted therapies that bring hope to some subpopulations of patients. Hence the interest in allowing each patient to access molecular biology tests to know the identity card of their tumor. In this area, France has a good territorial network of centers. The teams are thus able to identify, for example, a mutation in the ALK gene or even a mutation affecting the epidermal growth factor receptor (EGFR).

Information from the French to be strengthened

According to the Ipsos survey, half of the French today do not feel sufficiently informed about the main risk factors and the correct behaviors to adopt to limit the risk of contracting lung cancer. Many also claim that they are not sufficiently informed about diagnostic tests and treatment methods, particularly the latest therapeutic advances.

Non-specific symptoms

According to INCa [1]lung cancer symptoms ” it can combine breathing problems and unexplained deterioration in general condition »: Appearance of cough or increased cough of chronic bronchitis; bloody sputum; difficulty in breathing; recurrent lung infection; persistent fatigue; loss of appetite and weight… Finally, our specialist would like to mention the launch of the screening test programs. They are based on scanners and may in the future allow us to diagnose lung cancers earlier, treat them earlier, and then give us a better chance to cure them.

INCa, Lung cancer, possible symptoms – https://www.e-cancer.fr/Patients-et-proches/Les-cancers/Cancer-du-poumon/Symptomes – Site accessed on 21 October 2022

https://www.has-sante.fr/jcms/p_3312901/fr/depistage-du-cancer-du-poumon-la-has-recommand-l-engagement-d-un-programme-pilote

My lung cancer network: an association at your service

Laure Guéroult-Accolas, founded the Patients Network Association in 2014 and developed a specific aspect on lung cancer. This is a social network for people with lung cancer. The goal is to allow them to come out of the isolation linked to the disease, to compare themselves with other patients, to share their experience. At https://www.monreseau-cancerdupoumon.com/, they will also find reliable and quality information on the disease and its management.

Leave a Reply

Your email address will not be published. Required fields are marked *